top of page
MedMira Announces VYRAâ„¢ CoV2Flu and Additional Regulatory Opportunities
Halifax, Nova Scotia, 21 December, 2021 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the expansion of its VYRATMproduct line by...
MedMira
Dec 21, 20212 min read
MDSAP Certification
We are delighted to announce the receipt of the MDSAP certificate today. This highlights our firm and long lasting commitment to the...
MedMira
Dec 21, 20211 min read
MedMira strengthen its Board with New Appointment
Halifax, Nova Scotia, 17 December 2021 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announced today the appointment of Mr. Thomas Bergmann...
MedMira
Dec 17, 20213 min read
MedMira announces significant debt reduction and additional growth capital
Halifax, Nova Scotia, 14 December, 2021 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces a financial package of over $5.23 million...
MedMira
Dec 14, 20212 min read
Say Hello to VYRA CoV2Flu! Your answer to "Flurona"..
We are excited to introduce our latest product: VYRA CoV2Flu Rapid Antigen Test Quality, Speed, Ease-of-Use and Design combined - only...
MedMira
Dec 10, 20211 min read
Performance Update on World Health Organisation SARS-CoV2 Serology Standards
Halifax, Nova Scotia, 14 June, 2021 – MedMira Inc. (MedMira) (TSXV: MIR) announces the World Health Organization (WHO) SARS-CoV-2...
MedMira
Jun 13, 20212 min read
bottom of page